Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial
Sean Bennett, James McCarty, Roshan Ramanathan, Jason Mendy, Jason S. Richardson, Jonathan D. Smith, Jeff Alexander, Julie E. Ledgerwood, Paul-André de Lame, Sarah Royalty Tredo, Kelly L. Warfield, Lisa Bedell
Topics & Concepts
MedicineImmunogenicityVaccinationPopulationInternal medicineClinical endpointRandomized controlled trialGastroenterologyImmunologyAntibodyEnvironmental healthMosquito-borne diseases and controlHIV Research and TreatmentVirology and Viral Diseases